



JFW

PATENT  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Marlon D. Cowart

Serial No.: 10/656,672

Filed: September 5, 2003

For: BENZIMIDAZOLES THAT ARE USEFUL  
IN TREATING SEXUAL DYSFUNCTION

Examiner: (not assigned)

Group Art Unit: 1642

Attorney Docket No.: 6789.US.O3

Date: May 10, 2005

**Certificate of Mailing under 37 CFR §1.8(a):**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to:

Mailstop: Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450, on:

Date of Deposit: May 10, 2005

Wanda E. Smith 5/10/05  
Wanda E. Smith Date

TRANSMITTAL LETTER

Mailstop: Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith is a Supplemental Information Disclosure Statement for Marlon D. Cowart, for BENZIMIDAZOLES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION, the specification of which was filed on September 5, 2003, and received Serial No. 10/656,672.

Also enclosed are: Form PTO 1449 (in duplicate) w/4 (four) references  
Return-receipt postcard

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR 1.16, as well as any patent application processing fees under 37 CFR 1.17 associated with this communication for which full payment has not been tendered, to Deposit Account No. 01-0025. A duplicate copy of this sheet is enclosed.

23492

ABBOTT LABORATORIES  
Phone: (847) 935,4314  
FAX: (847) 938-2623

Respectfully submitted,

Marlon D. Cowart

Gabryleda Ferrari-Dileo  
Registration No. 55,174  
Attorney for Applicants



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Marlon D. Cowart

Serial No.: 10/656,672

Filed: September 5, 2003

For: BENZIMIDAZOLES THAT ARE USEFUL  
IN TREATING SEXUAL DYSFUNCTION

Examiner: (not assigned)

Group Art Unit: 1642

Attorney Docket No.: 6789.US.O3

Date: May 10, 2005

**Certificate of Mailing under 37 CFR §1.8(a):**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to:

Mailstop: Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450, on:

Date of Deposit: May 10, 2005

Wanda E. Smith 5/10/05  
Wanda E. Smith Date

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mailstop: Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This supplemental information disclosure statement is being filed before the mailing date of a first Office Action on the merits under 37 CFR § 1.97(b).

The Applicants submit herewith Form PTO 1449 listing the references cited for this Information Disclosure Statement.

The Applicants respectfully request that the Examiner initial next to each reference listed on the enclosed Form PTO 1449 indicating that the Examiner has considered and made those references of record in this application and that a copy of the initialed Form PTO 1449 be returned to Applicants.

No charge is required for the submission of this Information Disclosure Statement under 37 C.F.R. § 1.97 (b). The Commissioner is hereby authorized to charge any additional filing fees required under 37 C.F.R. § 1.17 concerning this transmission, or to credit any overpayment to Deposit Account No. 01-0025.


23492

ABBOTT LABORATORIES  
Phone: (847) 935,4314  
FAX: (847) 938-2623

Respectfully submitted,

Marlon D. Cowart

Gabryleda Ferrari-Dileo  
Registration No. P-55,174  
Attorney for Applicants



DATE: May 10, 2005

SHEET 1\_ of 1\_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Modified) PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

ATTY. DOCKET NO.

6789.US.O3

SERIAL NO.

10/656,672

APPLICANT(S)

M. D. Cowart, et al.

FILING DATE

September 5, 2003

GROUP

1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
B1 94/22839	13.10.94	WO			

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Berge, S.M. et al., J. Pharmaceutical Sciences 66:1et seq (1977)
C2	Padma-Nathan, H. et al., "Efficacy and safety of apomorphine SL vs. placebo for male erectile dysfunction," Urology 161:214 (abstract 821) (1999)
C3	Sule, D.P. et al., "Synthesis and Anthelmintic activity of 2-(N4-Substituted-N1-Piperazinyl) Methyl 5-(or 6) - substituted benzimidazoles," Bull. Haffkine Inst. 6(2):62-64 (1978)
C4	"IUPAC 1974 Recommendation for Section E, Fundamental Stereochemistry," Pure Appl. Chem. 45:13-30 (1976)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)